Table 1 Characteristics of the participants based on the original allocation to vitamin D or placebo group in the VIDEO trial at 60-month follow-up
Placebo (n = 81) | Vitamin D (n = 92) | |
|---|---|---|
Age, years | 66.7 (10.1) | 68.9 (6.9) |
Female, n (%) | 39 (48%) | 45 (49%) |
BMI, kg/m2 | 29.6 (12.1) | 27.9 (8.6) |
Knee surgerya, n (%) | 15 (19%) | 16 (17%) |
Total knee replacement, n (%) | 11 (14%) | 14 (15%) |
Vitamin D supplementation from 2014 to 2016 | ||
No regular use, n (%) | 45 (56%) | 64 (70%) |
Regular use for 1 or 2 years, n (%) | 16 (20%) | 11 (12%) |
Regular use for 3 years, n (%) | 20 (25%) | 17 (18%) |
Serum 25(OH)D levels, nmol/l | 60.6 (19.4) | 62.0 (18.4) |
Serum hs-CRP, mg/ml | 1.6 (1.3) | 2.3 (2.8) |
Serum IL6, ng/mL | 1.5 (3.3) | 1.3 (1.3) |
WOMAC | ||
Pain (0–500) | 91.7 (82.0) | 101.5 (96.3) |
Function (0–1700) | 318.4 (287.9) | 356.9 (351.2) |
Stiffness (0–200) | 45.9 (41.6) | 42.0 (44.0) |
Study knee VAS pain (0–100) | 32.8 (25.6) | 34.4 (29.2) |
AQoL utility (0–1) | 0.7 (0.2) | 0.7 (0.2) |
PHQ-9 (0–27) | 2.8 (2.9) | 3.1 (3.3) |
No depression, n (%) | 60 (74%) | 68 (74%) |
Mild depression, n (%) | 18 (22%) | 18 (20%) |
Moderate to severe depression, n (%) | 3 (4%) | 6 (7%) |
MET-min/week | 3971.9 (3632.0) | 3259.5 (3587.6) |
Physical activity categories | ||
Low | 18 (22.5%) | 24 (26.1%) |
Moderate | 20 (25.0%) | 31 (33.7%) |
High | 42 (52.5%) | 37 (40.2%) |